Diligence memo · auto-generated · as of July 2, 2026
Redpoint Bio CORP
Redpoint Bio CORP looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Redpoint Bio CORP operates in Biotechnology, based in PHILADELPHIA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Redpoint Bio CORP has raised $40M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $40M on 2012-07-16.
Most recent recorded round closed around 2012-07-16.
Valuation (modeled)modeled
Provath models Redpoint Bio CORP at approximately $1.6B (range $80M–$6.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.44× the median modeled value of Series B Biotechnology companies in 2010–2012 (48 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 14.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 79% of Biotechnology peers (4293 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: Cardiaq Valve Technologies Inc, Visterra, Inc., Celltex Therapeutics Corp, Crown Bioscience, Inc, Trius Therapeutics Inc.
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.